This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winters, M. A. Articles by Holodniy, M. Search for Related Content PubMed PubMed Citation Articles by Winters, M. A. Articles by Holodniy, M.

 Previous Article  |  Next Article 

Journal of Virology, April 2006, p. 4196-4199, Vol. 80, No. 8
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.8.4196-4199.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Hepatitis C Virus Protease Gene Diversity in Patients Coinfected with Human Immunodeficiency Virus

Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California,¹ Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts,² AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California³

Received 7 October 2005/ Accepted 1 February 2006

The clonal variability of the hepatitis C virus (HCV) protease gene in 24 individuals with HCV genotypes 1a, 1b, 2b, and 3a who were coinfected with the human immunodeficiency virus was evaluated. Within-genotype variability at the nucleotide and amino acid levels ranged from 6.5 to 8.6% and 2.2 to 3.8%, respectively. After adjustments were made for correlation of intrapatient clonal variation, mixed-model analysis indicated that nucleotide and amino acid variability among patients with different genotypes did not differ significantly. However, within individual patients, clonal variability differed by up to 5.3% and 5.8% at the nucleotide and amino acid levels, respectively, and genotype 1a had significantly greater nucleotide variability than other genotypes (P = 0.01). Significant variability exists within HCV protease gene variants at the patient level and could affect the effectiveness of HCV protease inhibitors.

This article has been cited by other articles:

• Pauwels, F., Mostmans, W., Quirynen, L. M. M., van der Helm, L., Boutton, C. W., Rueff, A.-S., Cleiren, E., Raboisson, P., Surleraux, D., Nyanguile, O., Simmen, K. A. (2007). Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors. J. Virol. 81: 6909-6919 [Abstract] [Full Text]